Drug intelligence / Profile preview

ephedrine + caffeine + aspirin

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral
01

Overview

The combination of ephedrine, caffeine, and aspirin, commonly referred to as the ECA stack, is a potent thermogenic formulation historically used for weight loss and athletic performance enhancement. Ephedrine acts as a sympathomimetic agent that stimulates the release of norepinephrine and directly activates adrenergic receptors, particularly the beta-3 subtype, to increase metabolic rate and lipolysis. Caffeine acts synergistically by inhibiting adenosine receptors and phosphodiesterase, which prevents the breakdown of cyclic AMP (cAMP) and prolongs the effects of norepinephrine. Aspirin is included to inhibit prostaglandin synthesis; prostaglandins normally provide a negative feedback loop that dampens the thermogenic response, so their inhibition allows for sustained metabolic activation. While effective for short-term weight reduction, the combination is associated with significant cardiovascular risks, including hypertension and arrhythmias, leading to its ban or severe restriction as a dietary supplement by the FDA and other international regulatory bodies.

Brand names
ECA StackECA EliteECA Xtreme
Other names
ECA stackEphedrine, caffeine, and aspirin combination
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)ADRB3 (β3)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on ephedrine + caffeine + aspirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ephedrine + caffeine + aspirin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call